-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Studies have shown that low-dose aspirin use may reduce cancer morbidity and mortality, but its effect on survival in gastric adenocarcinoma is unclear
.
A foreign team conducted a related study to evaluate whether taking aspirin after gastrectomy for gastric adenocarcinoma could improve long-term survival
This population-based cohort study included patients with gastric adenocarcinoma in Sweden who underwent gastrectomy from 2006 to 2015 and were followed up throughout 2020
.
Exposure to daily low-dose (75-160 mg) aspirin 1 year before surgery, 2 years, 3 years, and 1 year after gastrectomy was associated with 5-year all-cause mortality (primary outcome) and disease-specific mortality
Of the 2025 patients included in the study, 545 (26.
9%) used aspirin at the time of surgery
.
Of the patients taking aspirin, 178 (32.
Kaplan–Meier curves showed that there was no statistically significant difference in survival between patients taking and not taking aspirin
.
Use of aspirin within 1 year before surgery did not reduce the adjusted 5-year risk of all-cause mortality (HR = 0.
98, 95% CI 0.
85-1.
13) or disease-specific mortality (HR = 1.
00, 95% CI 0.
86-1.
17)
.
Taking aspirin within 2 years before surgery (HR = 0.
98, 95% CI 0.
84-1.
15) or within 3 years (HR = 0.
94, 95% CI 0.
79-1.
12) did not reduce the risk of 5-year all-cause mortality
.
Likewise, patients who used aspirin before surgery and 1 year after surgery did not experience any reduction in the risk of all-cause mortality at 5 years (adjusted HR=1.
In the sensitivity analysis, we excluded 291 (14.
3%) patients with gastrectomy without a clear therapeutic purpose
.
In an analysis of 1734 patients, the 90-day mortality rate was 4.
Taken together, studies suggest that low-dose aspirin use may not improve long-term survival after gastric adenocarcinoma surgery
Original source:
Holmberg D, Kauppila JH, Mattsson F, Asplund J, Leijonmarck W, Xie SH, Lagergren J.
leave a message here
